NewLimit logo

NewLimit

NewLimit is a biotechnology company focusing on developing epigenetic reprogramming therapies that aid with illnesses that are normally associated with aging.

2

Funding Rounds

$170.0m

Money raised

Overview

NewLimit is a biotechnology company focusing on developing epigenetic reprogramming therapies that aid with illnesses that are normally associated with aging.

Funding

Funding series

Funding Series Analysis

The company NewLimit has raised a total of $170m in funding over 2 rounds.

Key Insights:

  • NewLimit May 2025 Series B Funding Round: $130m
  • NewLimit Series A round, May 16, 2013: $40m
NewLimit logo
NewLimit May 2025 Series B Funding Round $130m
NewLimit logo
NewLimit Series A round, May 16, 2013 $40m

Industries

NewLimit is active in the following industries: